Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 2
2009 1
2010 2
2011 6
2012 13
2013 10
2014 6
2015 7
2016 4
2017 8
2018 10
2019 6
2020 8
2021 5
2022 12
2023 7
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 31644070

96 results

Results by year

Filters applied: . Clear all
Page 1
Belimumab.
[No authors listed] [No authors listed] 2020 Dec 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Dec 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644070 Free Books & Documents. Review.
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W; Belimumab Study Group. Furie R, et al. Arthritis Res Ther. 2008;10(5):R109. doi: 10.1186/ar2506. Epub 2008 Sep 11. Arthritis Res Ther. 2008. PMID: 18786258 Free PMC article. Clinical Trial.
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy.
Piantoni S, Regola F, Masneri S, Merletti M, Lowin T, Airò P, Tincani A, Franceschini F, Andreoli L, Pongratz G. Piantoni S, et al. Front Pharmacol. 2021 May 21;12:666971. doi: 10.3389/fphar.2021.666971. eCollection 2021. Front Pharmacol. 2021. PMID: 34093196 Free PMC article.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. Furie R, et al. Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. Arthritis Rheum. 2011. PMID: 22127708 Free PMC article. Clinical Trial.
Belimumab: in systemic lupus erythematosus.
Burness CB, McCormack PL. Burness CB, et al. Drugs. 2011 Dec 24;71(18):2435-44. doi: 10.2165/11208440-000000000-00000. Drugs. 2011. PMID: 22141386 Review.
Anifrolumab.
[No authors listed] [No authors listed] 2023 Sep 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Sep 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 37824693 Free Books & Documents. Review.
Belimumab in Systemic Lupus Erythematosus.
Srivastava A. Srivastava A. Indian J Dermatol. 2016 Sep-Oct;61(5):550-3. doi: 10.4103/0019-5154.190107. Indian J Dermatol. 2016. PMID: 27688447 Free PMC article.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group. Navarra SV, et al. Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4. Lancet. 2011. PMID: 21296403 Clinical Trial.
96 results